The stock of Delcath Systems, Inc. (NASDAQ:DCTH) reached all time low today, Oct, 28 and still has $1.74 target or 14.00% below today’s $2.02 share price. This indicates more downside for the $4.14M company. This technical setup was reported by Barchart.com. If the $1.74 PT is reached, the company will be worth $579,600 less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 72,529 shares traded hands or 69.48% up from the average. Delcath Systems, Inc. (NASDAQ:DCTH) has declined 50.00% since March 28, 2016 and is downtrending. It has underperformed by 54.71% the S&P500.
Analysts await Delcath Systems, Inc. (NASDAQ:DCTH) to report earnings on November, 8.
According to Zacks Investment Research, “Delcath Systems, Inc. has developed a system, the Delcath system, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver.”
Insitutional Activity: The institutional sentiment decreased to 1.13 in Q2 2016. Its down 0.30, from 1.43 in 2016Q1. The ratio fall, as 7 funds sold all Delcath Systems, Inc. shares owned while 1 reduced positions. 2 funds bought stakes while 7 increased positions. They now own 1.85 million shares or 18.13% less from 2.26 million shares in 2016Q1.
One Trading L P, a Illinois-based fund reported 5,123 shares. Wells Fargo & Communication Mn last reported 157 shares in the company. Goldman Sachs Group Inc owns 15,211 shares or 0% of their US portfolio. Moreover, Kcg has 0% invested in Delcath Systems, Inc. (NASDAQ:DCTH) for 12,403 shares. Private Advisor Group Inc Incorporated Limited Liability Corp has 206,670 shares for 0% of their US portfolio. Susquehanna Llp last reported 0% of its portfolio in the stock. Blackrock Institutional Na, a California-based fund reported 531,871 shares. Barclays Public Limited has 15 shares for 0% of their US portfolio. National Bank Of America Corporation De, a North Carolina-based fund reported 4,604 shares. Creative Planning last reported 307 shares in the company. Royal Fincl Bank Of Canada accumulated 2,563 shares or 0% of the stock. The Florida-based Ladenburg Thalmann Inc has invested 0% in Delcath Systems, Inc. (NASDAQ:DCTH). Geode Cap Mngmt owns 39,792 shares or 0% of their US portfolio. Deutsche Bank Ag last reported 0% of its portfolio in the stock. Renaissance Limited Co reported 754,998 shares or 0% of all its holdings.
More notable recent Delcath Systems, Inc. (NASDAQ:DCTH) news were published by: Marketwatch.com which released: “Delcath Systems Inc.” on December 22, 2009, also Prnewswire.com with their article: “Delcath Announces New U.S. Clinical Sites For FOCUS Phase 3 Trial For Ocular …” published on October 11, 2016, Prnewswire.com published: “European Data Supporting Survival Benefit With Delcath’s CHEMOSAT System …” on July 06, 2016. More interesting news about Delcath Systems, Inc. (NASDAQ:DCTH) were released by: Globenewswire.com and their article: “Pomerantz Law Firm Has Filed a Class Action Against Delcath Systems, Inc. and …” published on May 08, 2013 as well as Prnewswire.com‘s news article titled: “Delcath Announces Initiation Of Phase 3 Trial Of Melphalan/HDS System For …” with publication date: January 20, 2016.
DCTH Company Profile
Delcath Systems, Inc., incorporated on August 5, 1988, is a late-stage clinical development firm with early commercial activity in Europe focused on cancers of the liver. The Firm is a specialty pharmaceutical and medical device firm developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.